AN2 Therapeutics (ANTX) Other Working Capital Changes (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Other Working Capital Changes of $267000.0 for Q1 2026, up 141.4% year-over-year from $110606.9 in Q1 2025, and up 267.92% quarter-over-quarter from -$159000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Other Working Capital Changes (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Other Working Capital Changes for 6 consecutive years, with $267000.0 the latest figure, recorded in Q1 2026.
- In Q3 2023, Other Working Capital Changes rose 35.0% year-over-year to -$13000.0; the TTM figure through Dec 2023 stood at -$53000.0 (up 31.17% YoY), while the FY2025 annual figure was $170000.0, changed N/A from the prior year.
- Other Working Capital Changes improved to -$13000.0 in Q3 2023 per ANTX's latest filing, from -$21000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at -$13000.0 in Q3 2023 and bottomed at -$21000.0 in Q2 2023.
- Historically, Other Working Capital Changes has averaged $38352.9 across 5 years, with a median of -$21000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes jumped 1633.33% — and 2025, when it plunged 880.43%.
- AN2 Therapeutics' Other Working Capital Changes stood at -$20000.0 in 2022, then jumped by 35.0% to -$13000.0 in 2023.
- Business Quant data shows ANTX's Other Working Capital Changes at -$13000.0 in Q3 2023, -$21000.0 in Q2 2023, and -$19000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -719,000.00 |
| Jun 30, 2026 | -719,000.00 |
| Mar 31, 2026 | 267,000.00 |
| Mar 31, 2026 | 267,000.00 |
| Dec 31, 2025 | -159,000.00 |
| Dec 31, 2025 | -159,000.00 |
| Sep 30, 2025 | -2.51 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | -645,000.00 |
| Mar 31, 2025 | -645,000.00 |
| Dec 31, 2024 | -815,000.00 |
| Dec 31, 2024 | -815,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 795,000.00 |
| Jun 30, 2024 | 795,000.00 |
| Mar 31, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.11 Mn |